Nanocarriers for the vascular delivery of drugs to the lungs

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 499-526

  Dziubla, Thomas ^a,b   Muzykantov, Vladimir ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANO-CARRIERS;

DRUG DELIVERY;

EID: 84903658901     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0023     Document Type: Chapter

References (125)

1. Muzykantov VR (2001) Delivery of antioxidant enzyme proteins to the lung. Antiox Redox Signal 3:39-62.
2. Fishman AP (2004) A century of pulmonary hemodynamics. Am J Respir Crit Care Med 170:109-113.
3. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK and Prasad B (2003) Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52:981-986.
4. Corkery K (2000) Inhalable drugs for systemic therapy. Respir Care 45:831-835.
5. Knecht A (1991) Inhalation therapy: alternative systems-an overview. J Aerosol Med 4:189-192.
6. Patton J (1998) Breathing life into protein drugs. Nat Biotechnol 16:141-143.
7. Rau JL (2005) The inhalation of drugs: advantages and problems. Respir Care 50:367-382.
8. Muzykantov VR (2003) Targeting pulmonary endothelium, in Muzykantov VR and Torchilin VP (eds.) Biomedical Aspects of Drug Targeting. Kluwer Academic Publishers: Boston, pp. 129-148.
9. Muzykantov VR (2001) Targeting of superoxide dismutase and catalase to vascular endothelium. J Control Rel 71:1-21.
10. Dziubla TD, Muro S, Muzykantov VR and Koval M (2005) Nanoscale Antioxidant Therapeutics, in Singh KK (ed.) Oxidative Stress, Disease and Cancer. Imperial College Press: London, in Press.
11. Brantley-Sieders D, Parker M and Chen J (2004) Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 10:3431-3442.
12. Bibby DC, Talmadge JE, Dalai MK, Kurz SG, Chytil KM, Barry SE, Shand DG and Steiert M (2005) Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 293:281-290.
13. Stevens PJ, Sekido M and Lee RJ (2004) A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 21:2153-2157.
14. Benns JM and Kim SW (2000) Tailoring new gene delivery designs for specific targets. J Drug Targ 8:1-12.
15. Muro S, Koval M and Muzykantov V (2004) Endothelial endocytic pathways: Gates for vascular drug delivery. Curr Vase Pharmacol 2:281-299.
16. Murciano JC, Muro S, Koniaris L, Christofidou-Solomidou M, Harshaw DW, Albelda SM, Granger DN, Cines DB and Muzykantov VR (2003) ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 101:3977-3984.
17. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V and Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
18. Kreuter J, Tauber U and Illi V (1979) Distribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. J Pharm Sci 68:1443-1447.
19. Moghimi SM, Hunter AC and Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283-318.
20. Harris JM (1992) Poly(ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. Plenum Press: New York.
21. Moghimi SM and Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463-478.
22. Forster S, Konrad M and Linder P (2005) Shear thinning and orientational ordering of wormlike micelles. Phys Rev Lett 94:017803.
23. Li S, Nickels J and Palmer AF (2005) Liposome-encapsulated actin-hemoglobin (LEAcHb) artificial blood substitutes. Biomαteriαls 26:3759-3769.
24. Li S and Palmer AF (2004) Structure of small actin-containing liposomes probed by atomic force microscopy: Effect of actin concentration & liposome size. Lαngmuir 20:7917-7925.
25. Yoon W (2004) Embolic agents used for bronchial artery embolisation in massive haemoptysis. Exp Opin Phαrmαcother 5:361-367.
26. Kumar N, Ravikumar MN and Domb AJ (2001) Biodegradable block copolymers. Adv Drug De Rev 53:23-44.
27. Heller J and Baker RW (1980) Theory and Practice of Controled Drug Delivery from Bio-erodible Polymers, in Baker RW (ed.) Controled Release of Bioactive Materials. Academic Press: New York: 1-37.
28. Dziubla TD and Muzykantov V (2006) Synthetic carriers for the delivery of protein therapeutics. Biotechnol Genet Eng Rev 22:267-299.
29. Bragonzi A, Boletta A, Biffi A, Muggia A, Sersale G, Cheng SH, Bordignon C, Assael BM and Conese M (1999) Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs. Gene Ther 6:1995-2004.
30. Floch V, Delepine P, Guillaume C, Loisel S, Chasse S, Le Bolc’h G, Gobin E, Leroy JP and Ferec C (2000) Systemic administration of cationic phosphonolipids/DNA complexes and the relationship between formulation and lung transfection efficiency. Biochim Biophys Acta 1464:95-103.
31. Ravi Kumar MN, Sameti M, Mohapatra SS, Kong X, Lockey RF, Bakowsky U, Lindenblatt G, Schmidt H and Lehr CM (2004) Cationic silica nanoparticles as gene carriers: Synthesis, characterization and transfection efficiency in vitro and in vivo. J Nanosci Nanotechnol 4:876-881.
32. Kwok KY, Yang Y and Rice KG (2001) Evolution of cross-linked non-viral gene delivery systems. Curr Opin Mol Ther 3:142-146.
33. Benigni A, Tomasoni S and Remuzzi G (2002) Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. Kidney Int 61:115-119.
34. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC and Mahan LC (1995) Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 92:9742-9746.
35. Rodman DM, San H, Simari R, Stephan D, Tanner F, Yang Z, Nabel GJ and Nabel EG (1997) In vivo gene delivery to the pulmonary circulation in rats: transgene distribution and vascular inflammatory response. Am J Respir Cell Mol Biol 16:640-649.
36. Torchilin VP (2000) Drug targeting. Eur J Pharm Sci 11 (Suppl 2):S81-S91.
37. Fang J, Sawa T and Maeda H (2003) Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 519:29-49.
38. Maeda H, Fang J, Inutsuka T and Kitamoto Y (2003) Vascular permeability enhancement in şolid tumor: Various factors, mechanisms involved and its implications. Int Immunopharmacol 3:319-328.
39. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE and Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429:629-635.
40. Muzykantov VR, Puchnina EA, Atochina EN, Hiemish H, Slinkin MA, Meertsuk FE and Danilov SM (1991) Endotoxin reduces specific pulmonary uptake of radiolabeled monoclonal antibody to angiotensin-converting enzyme. J Nucl Med 32:453-460.
41. Trubetskoy VS, Torchilin VP, Kennel SJ and Huang L (1992) Use of N-terminal modified poly(L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells. Bioconjug Chem 3:323-327.
42. Schuchman E and Muro S (2005) The development of enzyme replacement therapy for lysosomal diseases: Gaucher disease and beyond, in Futerman T and Zimran A (eds.) Gaucher Disease: Lessons Learned About Therapy of Lysosomal Diseases. CRC Press: Boca Raton, in Press.
43. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R and Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430-437.
44. Danilov SM, Gavrilyuk VD, Franke FE, Pauls K, Harshaw DW, McDonald TD, Miletich DJ and Muzykantov VR (2001) Lung uptake of antibodies to endothelial antigens: Key determinants of vascular immunotargeting. Am J Physiol 280:L1335-L1347.
45. Danilov S, Atochina E, Hiemisch H, Churak-ova T, Moldobayeva A, Sakharov I, Deichman G, Ryan U and Muzykantov VR (1994) Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: Antibody targeting to the lung induces ACE antigenic modulation. Int Immunol 6:1153-11560.
46. Danilov SM, Muzykantov VR, Martynov AV, Atochina EN, Sakharov IY, Trakht IN and Smirnov VN (1991) Lung is the target organ for a monoclonal antibody to angiotensin-converting enzyme. Lab Invest 64:118-124.
47. Muzykantov VR, Christofidou-Solomidou M, Balyasnikova I, Harshaw DW, Schultz L, Fisher AB and Albelda SM (1999) Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody platelet-endothelial cell adhesion molecule (1): A strategy for vascular immunotargeting of drugs. Proc Nat Acad Sci USA 96:2379-2384.
48. Muro S, Gajewski C, Koval M and Muzykantov VR (2005) ICAM-1 recycling in endothelial cells: A novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 105:650-658.
49. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L and Weissleder R (2005) Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 96:327-336.
50. Sakhalkar HS, Dalai MK, Salem AK, Ansari R, Fu J, Kiani MF, Kurjiaka DT, Hanes J, Shakesheff KM and Goetz DJ (2003) Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci USA 100:15895-15900.
51. Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, Meijer DK, Haisma HJ and Molema G (2004) A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 15:433-443.
52. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, Gurtner GC, Cybulsky MI, Tosi PF, Nicolau C and Gimbrone MA, Jr. (1997) Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA 94:8795-8800.
53. Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F and Ley K (2001) Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 104:2107-2112.
54. Predescu D, Predescu S and Malik AB (2002) Transport of nitrated albumin across continuous vascular endothelium. Proc Natl Acad Sci USA 99:13932-13937.
55. Durr E, Yu J, Krasinska KM, Carver LA, Yates JR, Testa JE, Oh P and Schnitzer JE (2004) Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 22:985-992.
56. McIntosh DP, Tan XY, Oh P and Schnitzer JE (2002) Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci USA 99:1996-2001.
57. Disegi JA (2000) Titanium alloys for fracture fixation implants. Injury 31 (Suppl 4):14-17.
58. Gotman I (1997) Characteristics of metals used in implants. J Endourol 11: 383-389.
59. Gole J, Burda C, Fedorov A and White M (2003) Enhanced reactivity and phase transformation at the nanoscale: Efficient formation of active silica and doped and metal seeded TiO2-xNx photocatalysts. Rev Adv Mater Sci 5:265-269.
60. Oberdorster G, Finkelstein JN, Johnston C, Gelein R, Cox C, Baggs R and Elder AC (2000) Acute pulmonary effects of ultrafine particles in rats and mice. Res Rep Health Eff Inst 5-74; 75-86.
61. Warner WG, Yin JJ and Wei RR (1997) Oxidative damage to nucleic acids photosensitized by titanium dioxide. Free Radic Biol Med 23:851-858.
62. Borm PJ and Kreyling W (2004) Toxicological hazards of inhaled nanoparticles - potential implications for drug delivery. J Nanosci Nanotechnol 4:521-531.
63. Thanou M and Duncan R (2003) Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Invest Drugs 4:701-709.
64. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347360.
65. Muller NL (2002) Computed tomography and magnetic resonance imaging: past, present and future. Eur Respir J (Suppl)35:3s-12s.
66. Kauczor HU and Kreitner KF (2000) Contrast-enhanced MRI of the lung. Eur J Radiol 34:196-207.
67. Mclntire GL, Bacon ER, Illig KJ, Coffey SB, Singh B, Bessin G, Shore MT and Wolf GL (2000) Time course of nodal enhancement with CT X-ray nanoparticle contrast agents: Effect of particle size and chemical structure. Invest Radiol 35:91-96.
68. Wisner ER, Katzberg RW, Koblik PD, Shelton DK, Fisher PE, Griffey SM, Drake C, Harnish PP, Vessey AR, Haley PJ, et al. (1994) Iodinated nanoparticles for indirect computed tomography lymphography of the craniocervical and thoracic lymph nodes in normal dogs. Acad Radiol 1:377-384.
69. Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC, Jr., Botnar RM, Weisskoff RM, Graham PB, Manning WJ and Gunther RW (2005) Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 111:1377-1382.
70. Choi H, Choi SR, Zhou R, Kung HF and Chen IW (2004) Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 11:996-1004.
71. Martins S, de Perrot M, Imai Y, Yamane M, Quadri SM, Segall L, Dutly A, Sakiyama S, Chaparro A, Davidson BL, Waddell TK, Liu M and Keshavjee S (2004) Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant model. Gene Ther 11:1786-1796.
72. Suda T, Mora BN, D’Ovidio F, Cooper JA, Hiratsuka M, Zhang W, Mohanakumar T and Patterson GA (2000) In vivo adenovirus-mediated endothelial nitric oxide synthase gene transfer ameliorates lung allograft ischemia-reperfusion injury. J Thorac Cardiovasc Surg 119:297-304.
73. Hiratsuka M, Mora BN, Yano M, Mohanakumar T and Patterson GA (1999) Gene transfer of heat shock protein 70 protects lung grafts from ischemia-reperfusion injury. Ann Thorac Surg 67:1421-1427.
74. Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balyasnikova IV, Baker AH, Danilov SM and Curiel DT (2001) Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 19:838-842.
75. Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM and Curiel DT (2000) A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2:562-578.
76. Wagner E (2004) Strategies to improve DNA polyplexes for in vivo gene transfer: Will “artificial viruses” be the answer? Pharm Res 21:8-14.
77. Elouahabi A and Ruysschaert JM (2005) Formation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther 11:336-347.
78. Rodriguez EG (2004) Nonviral DNA vectors for immunization and therapy: Design and methods for their obtention. J Mol Med 82:500-509.
79. Griesenbach U, Geddes DM and Alton EW (2004) Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med 10:542-546.
80. Barron LG, Uyechi LS and Szoka FC, Jr. (1999) Cationic lipids are essential for gene delivery mediated by intravenous administration of lipoplexes. Gene Ther 6:1179-1183.
81. Li S, Tan Y, Viroonchatapan E, Pitt BR and Huang L (2000) Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am J Physiol Lung Cell Mol Physiol 278:L504-511.
82. Balyasnikova IV, Yeomans DC, McDonald TB and Danilov SM (2002) Antibody-mediated lung endothelium targeting: In vivo model on primates. Gene Ther 9:282-290.
83. Balyasnikova IV, Metzger R, Visintine DJ, Dimasius V, Sun ZL, Berestetskaya YV, McDonald TD, Curiel DT, Minshall RD and Danilov SM (2005) Selective rat lung endothelial targeting with a new set of monoclonal antibodies to angiotensin I-converting enzyme. Pulm Pharmacol Ther 18:251-267.
84. Gopalan B, Ito I, Branch CD, Stephens C, Roth JA and Ramesh R (2004) Nanoparticle based systemic gene therapy for lung cancer: Molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 3: 647-657.
85. Li S, Wu SP, Whitmore M, Loeffert EJ, Wang L, Watkins SC, Pitt BR and Huang L (1999) Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 276:L796-804.
86. Kozower BD, Christofidou-Solomidou M, Sweitzer TD, Muro S, Buerk DG, Solomides CC, Albelda SM, Patterson GA and Muzykantov VR (2003) Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol 21:392-398.
87. Christofidou-Solomidou M, Scherpereel A, Wiewrodt R, Ng K, Sweitzer T, Arguiri E, Shuvaev V, Solomides CC, Albelda SM and Muzykantov VR (2003) PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol 285:L283-L292.
88. Dziubla TD, Karim A and Muzykantov VR (2005) Polymer nanocarriers protecting active enzyme cargo against proteolysis. J Control Rel 102:427-439.
89. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD and Bally MB (2005) The liposomal formulation of doxorubicin. Meth Enzymol 391:71-97.
90. Stone WL and Smith M (2004) Therapeutic uses of antioxidant liposomes. Mol Biotechnol 27:217-230.
91. Spina D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63:2575-2594.
92. Peer D and Margalit R (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6:343-353.
93. Lu B, Zhang JQ and Yang H (2003) Lung-targeting microspheres of carboplatin. Int J Pharm 265:1-11.
94. Mainardes RM and Silva LP (2004) Drug delivery systems: Past, present, and future. Curr Drug Targ 5:449-455.
95. Panyam J and Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev 55:329-347.
96. Ulrich AS (2002) Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 22:129-150.
97. Hans ML and Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Current Opin Solid State Mater Sci 6:319-327.
98. Discher DE and Eisenberg A (2002) Polymer Vesicles. Science 297:967-973.
99. Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A and Akashi M (2002) Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm 239:185-195.
100. Constancis A, Meyrueix R, Bryson N, Huille S, Grosselin JM, Gulik-Krzywicki T and Soula G (1999) Macromolecular colloids of diblock poly(amino acids) that bind insulin. J Coll Interf Sci 217:357-368.
101. Lvov Y and Caruso F (2001) Biocolloids with ordered urease multilayer shells as enzymatic reactors. Anal Chem 73:4212-4217.
102. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR and Koval M (2003) A novel endocytic pathway induced by clustering endothelial ICAM-1 or PEC AM-1. J Cell Sci 116:1599-1609.
103. Michaelis M, Matousek J, Vogel JU, Slavik T, Langer K, Cinatl J, Kreuter J and Schwabe D (2000) Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro. Anticancer Drugs 11:369-376.
104. Bousquet Y, Swart PJ, Schmitt-Colin N, Velge-Roussel F, Kuipers ME, Meijer DK, Bru N, Hoebeke J and Breton P (1999) Molecular mechanisms of the adsorption of a model protein (human serum albumin) on poly(methylidene malonate 2.1.2) nanoparticles. Pharm Res 16:141-147.
105. Muro S, Muzykantov VR and Murciano JC (2004) Characterization of endothelial internalization and targeting of antibody-enzyme conjugates in cell cultures and in laboratory animals. Meth Mol Biol 283:21-36.
106. Ceh B, Winterhalter M, Frederik PM, Vallner JJ and Lasic DD (1997) Stealth Liposomes: From theory to product. Adv Drug Del Rev 24:165-177.
107. Discher BM, Won Y-Y, Ege DS, Lee CC-M, Bates FS, Discher DE and Hammer DA (1999) Polymersomes: Tough vesicles made from Diblock copolymers. Science 284:143-146.
108. Huang G, Gao J, Hu Z, St John JV, Ponder BC and Moro D (2004) Controlled drug release from hydrogel nanoparticle networks. J Control Rel 94:303-311.
109. Peppas NA, Wood KM and Blanchette JO (2004) Hydrogels for oral delivery of therapeutic proteins. Exp Opin Biol Ther 4:881-887.
110. Onishi H and Machida Y (2003) Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol Pharm Bull 26:116-119.
111. Klibanov AM (2001) Improving enzymes by using them in organic solvents. Nature 409:241-246.
112. Klibanov AM (1997) Why are enzymes less active in organic solvents than in water? Trends Biotechnol 15:97-101.
113. Harada A and Kataoka K (2001) Pronounced activity of enzymes through the incorporation into the core of polyion complex micelles made from charged block copolymers. J Control Rel 72:85-91.
114. Godbey WT, Wu KK and Mikos AG (1999) Poly(ethylenimine) and its role in gene delivery. J Control Rel 60:149-160.
115. Kopecek J, Kopeckova P, Minko T, Lu ZR and Peterson CM (2001) Water soluble polymers in tumor targeted delivery. J Control Rel 74:147-158.
116. Hoste K, De Winne K and Schacht E (2004) Polymeric prodrugs. Int JPharm 277:119-131.
117. Ulbrich K and Subr V (2004) Polymeric anticancer drugs with pH-controlled activation. Adv Drug Del Rev 56:1023-1050.
118. Shuvaev VV, Dziubla T, Wiewrodt R and Muzykantov VR (2004) Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: Nanoconjugates for protection against endothelial oxidative stress. Meth Mol Biol 283:3-19.
119. Dziubla TD and Lowman AM (2001) Gels, in Schwartz M (ed.) Encyclopedia of Smart Materials. Wiley and Sons: New York: 1-12.
120. Lowman AM, Dziubla TD, Bures P and Peppas NA (2004) Structural and dynamic response of neutral and intelligent networks in biomedical environments, in Peppas NA and Sefton MV (eds.) Advances In Chemical Engineering: Molecular and Cellular Foundations of Biomaterials. Academic Press: New York, 29:75-122.
121. Wiewrodt R, Thomas AP, Cipelletti L, Christofidou-Solomidou M, Weitz DA, Feinstein SI, Schaffer D, Albelda SM, Koval M and Muzykantov VR (2002) Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood 99:912-922.
122. Torchilin VP (1994) Immunoliposomes and PEGylated immunoliposomes: Possible use for targeted delivery of imaging agents. Immunomethods 4:244-258.
123. Hermanson GT (1996) Bioconjugate Techniques. Acedemic Press: San Diego, CA.
124. Olivier JC, Huertas R, Lee HJ, Calon F and Pardridge WM (2002) Synthesis of pegylated immunonanoparticles. Pharm Res 19:1137-1143.
125. Tessmar J, Mikos A and Gopferich A (2003) The use of poly(ethylene glycol)-block-poly(lactic acid) derived copolymers for the rapid creation of biomimetic surfaces. Biomaterials 24:4475-4486.